个性化、剂量节约型乙型肝炎疫苗无应答者再接种策略评价
研究比较四种抗-HBs检测方法在初种无应答者中区分抗体缺失与低水平抗体的能力,并评估基于滴度的再接种策略。57名无应答者接受Fendrix 20 μg于0、1、2月再接种,滴度指导策略较标准三剂方案减少17%再接种量。
要点
- 除ADVIA外各检测方法间一致性Kappa≥0.65。
- 再接种一剂后零应答者血清转化率42.9%,弱应答者85.1%。
- 三剂后零应答者88.2%,弱应答者98.5%,各检测方法间差异不显著。
核心结论
- 所有检测方法均显示再接种一剂后零应答者与弱应答者血清转化率存在可比差异,可通过区分零应答与弱应答并采用滴度指导方案优化再接种策略。
研究设计与样本
- 研究纳入57名初种无应答者,于0、1、2月接种Fendrix 20 μg进行再接种。
- 采用Abbott Architect、Diasorin Liaison、Roche Cobas和Siemens ADVIA Centaur四种方法检测抗-HBs滴度。
- 以Cohen Kappa评估基线样本中零应答者(无 detectable 抗体)与弱应答者(可检测抗体<10 IU/L)的检测方法间一致性。
- 分析0、1、3月时的血清转化率和几何平均滴度。
- 比较基于滴度的策略(再接种一剂并测抗-HBs,必要时再接种两剂)与标准三剂再接种方案。
主要发现
- 除ADVIA外所有检测方法的Kappa≥0.65,ADVIA的Kappa≤0.41。
- 再接种一剂后,各检测方法检测零应答者的平均血清转化率为42.9%,弱应答者为85.1%。
- 每种检测方法下零应答者与弱应答者的血清转化率差异显著(p<0.05)。
- 再接种三剂后,零应答者平均血清转化率为88.2%,弱应答者为98.5%(每种检测方法p>0.286)。
- 基于滴度的策略较标准方案减少17%的再接种量。
关键数值与推荐
- 再接种方案为Fendrix 20 μg于0、1、2月接种。
- 抗-HBs低水平定义为<10 IU/L。
- 检测方法间一致性Kappa≥0.65为可接受,ADVIA的Kappa≤0.41。
- 再接种一剂后零应答者与弱应答者血清转化率差异p<0.05。
- 再接种三剂后零应答者与弱应答者血清转化率差异p>0.286。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The detection of low levels of antibodies against HBsAg (anti-HBs) below 10 IU/L in non-responders after a primary hepatitis B vaccination, is associated with seroconversion after revaccination. We compared the diagnostic performance of four anti-HBs assays in non-responders in their ability to differentiate between absence or presence of low levels of anti-HBs and propose a revaccination strategy guided by anti-HBs titres. METHODS: Non-responders were revaccinated with Fendrix 20 μg at 0, 1 and 2 months. Anti-HBs titres were determined by Abbott Architect, Diasorin Liaison, Roche Cobas and Siemens ADVIA Centaur. Inter-assay agreement was evaluated with Cohen's Kappa (k) in baseline samples between zero-responders without detectable antibodies and poor-responders with detectable antibodies < 10 IU/L. Seroconversion rates and geometric mean titres were analysed at 0, 1 and 3 months. A titre-based strategy (one revaccination dose and anti-HBs measurement followed by two more revaccination doses if required) was compared with the standard revaccination series of 3 doses. RESULTS: 57 participants were included in the analysis. k was ≥ 0.65 for all assays except ADVIA (k ≤ 0.41). After one revaccination dose all assays detected a mean seroconversion rate in zero-responders of 42.9%, compared to 85.1% in poor-responders. The difference between zero- and poor-responders in seroconversion rate per assay was significant (p < 0.05). After three revaccination doses the mean seroconversion rate was 88.2% in zero-responders and 98.5% in poor-responders (p > 0.286 per assay). A titre-based strategy reduced the amount of revaccinations by 17% compared with the standard. CONCLUSIONS: All assays demonstrated a comparable difference in seroconversion rate between zero- and poor-responders after one revaccination dose. The revaccination strategy could be optimised by differentiation between zero- and poor-responders followed by a titre-guided schedule.
引用
- Beulens C, Raven SFH, van Jaarsveld CHM, et al. Evaluation of a personalized, dose-sparing revaccination strategy in hepatitis B vaccine non-responders. Vaccine. 2022. PMID: 35469696. doi:10.1016/j.vaccine.2022.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。